Fortunate to be nominated by the business and industry community,
Alagate Limited has awarded as Asia's Most Valuable Companies in Hong Kong Awards 2026 -《 Most Trusted Drug Testing and Certification Partner 》.
Details: Award’s official website - Facebook - Instagram - X.com (Twitter) - LinkedIn
"The Incident of Wang Fuk Court, Tai Po"
To support those affected by the unfortunate accident at Wang Fuk Court in Tai Po, our company has donated HK$100,000 to Tung Wah Group of Hospitals,
hoping to help those in need within Wang Fuk Court.
Tung Wah Group of Hospitals 155th Anniversary
link: Click here
The following is issued on behalf of the Chinese Medicine Council of Hong Kong (CMCHK):
The CMCHK announced today (June 24) that the evaluation and approval process for converting the transitional registrations of proprietary Chinese medicines (pCm) to formal registrations has been completed. The transitional registration system for pCm will come to an end on June 30. By then, all pCms sold in Hong Kong must have valid formal registrations, marking a new chapter in the regulatory regime of Chinese medicine in Hong Kong.
According to the Chinese Medicine Ordinance (Cap. 549), all pCms must be registered with the Chinese Medicines Board (CMB) under the CMCHK before they can be sold, imported or possessed in Hong Kong. The registration of pCm must comply with the stringent requirements of the CMB in respect of safety, quality and efficacy. Taking into account the actual situation of the trade, the Government implemented a transitional measure in the past. PCms manufactured or sold in Hong Kong as of March 1, 1999, and meeting the eligibility criteria for transitional registration, were allowed to continue to be sold during the application period for "Certificate of registration of pCm" (HKC) with a "Notice of confirmation of transitional registration of pCm" (HKP).
During the implementation of the transitional registration arrangement, the CMB processed a total of 14 172 cases of HKP applications and approved 9 150 for issuance of HKP. Among these cases, 6 174 cases were successfully issued with HKC, while the remaining 2 976 cases were not issued with HKCs due to reasons such as the applicants' failure to submit the required information, withdrawal of applications by the applicants, or revocation of the HKPs, among others.
In view of the time taken by the trade to adapt to the registration requirements and the impact of the pandemic, the CMB extended the deadline for submission of registration information on a number of occasions. In February 2024, the CMB made a final decision that all applications for HKC from HKP must be completed by June 30, 2025. After that, HKP will be revoked for overdue cases, and the products concerned will not be allowed to be sold, imported, or possessed in Hong Kong.
Information source from: The Government of the HKSAR
link: Click here
"Alagate CM Fund" sponsored and supported the second Chinese medicine special dinner organized by The Hong Kong Society of Chinese Medicines -"粵港澳大灣區的最新藥品政策和實例", which raised everyone's awareness of the simple registration of proprietary Chinese medicines in the Greater Bay Area and opportunities to deepen understanding and promote the development of the industry.
The Chinese Medicine Unit of the Health Bureau, The Hong Kong Special Administrative Region Government, is committed to formulating the " Chinese Medicine Development Blueprint " and appointed Dr Vincent Chung Chi-ho as the Commissioner for Chinese Medicine Development on May 20 of 2024, responsible for jointly formulating the "Blueprint" with the Chinese medicine industry.
Our company is honored to have a dedicated representative from the "Chinese Medicine Unit" visit to discuss and put forward important opinions, issues, developments, and prospects of the Chinese medicine industry to the Bureau, to assist in formulating the "Blueprint".
The Chinese Medicine Council of Hong Kong has revised the safety standard limits for harmful residues (including heavy metals and toxic elements) in Chinese herbal medicines in Hong Kong. The new standards have come into effect on December 31, 2023, and a 12-month grace period has been set up (that is, until December 30, 2024).
In response to this standard and customer demand, we can now provide HOKLAS accreditation reports for testing heavy metals and toxic elements in decoctions of Chinese medicinal materials, including 17 designated Chinese medicinal materials and the remaining 588 types of Chinese medicinal materials scheduled under the Ordinance.
In order to promote the development of the Chinese medicine industry, ensure the quality, safety and efficacy of proprietary Chinese medicines, and to improve the supervision of Chinese medicine activities, Macau has promulgated Law No. 11/2021 and Administrative Regulation No. 46/2021 in 2021. Relevant laws and regulations have come into effect on January 1, 2022. All proprietary Chinese medicines sold in Macau must be registered (MAC).
Fortunate to be nominated by the business and industry community, Alagate Limited has awarded as HONG KONG'S MOST OUTSTANDING BUSINESS AWARDS 2022-《Most Outstanding Consultancy Service Of Chinese Medicine and Food Supplement Industries》in 2022.
Fortunate to be nominated by the business and industry community, Alagate Limited has awarded as Asia's Most Valuable Companies in Hong Kong Awards 2022-《Asia’s Most Innovative Drugs Testing and Certification Services》in 2022.
See how their innovation is helping the healthcare sector save lives on
Mediazone - Facebook - Instagram - Twitter - LinkedIn
Our CEO, Dr. Albert Tsang has invited by Shui On-Yau Lee Joint Venture as Consultant for providing Laboratory Consultancy on Design and Construction of Chinese Medicine Hospital and Government Chinese Medicines Testing Institute in Tseung Kwan O.
Alagate has been successfully granted for more than 135 client’s HKP/HKC products from Chinese Medicine Development Fund
艾爾奇已成功協助客戶的135種 HKP / HKC產品獲得中藥發展基金資助註冊
Alagate has been successfully registered as Chinese Medicine Development Fund (香港中醫藥發展基金) Proprietary Chinese Medicine Registration Supporting Scheme-Service Provider (「中成藥註冊支援計劃」服務提供者) (Registration No.登記編號：19A3C0002).
Detail
Consultation document on "setting limits of sulphur dioxide residue in Chinese herbal medicines and related measures for implementation".
衞生署有關制定中藥材二氧化硫殘留限度及相關執行方案的建議
DetailProposal on amendment of the definition of "proprietary Chinese medicine" under "Chinese Medicine Ordinance (Cap.549)" (Chinese version only)
衞生署修訂《中醫藥條例》 中成藥定義座談會 及 建議修訂《中醫藥條例》(第549章) 內容
Detailrepresent Chinese medicines industry to invite Dr. TSUI Lok-Kin (Assistant Director, Traditional Chinese Medicine) of Department of Health to discuss the difficulties and problems on Chinese Medicines registration.
代表中藥業界約見徐樂堅醫生(中醫藥事務部助理署長)討論有關中成藥註冊制度中業界遇到之問題
Our CEO, Dr. Albert Tsang has invited by Po Leung Kuk Ngan Po Ling College as School Consultant for the development of Chinese Medicine Testing Centre and its applications on the studies of Chinese Medicines.
本公司之行政總裁曾銳博士,獲保良局顏寶鈴書院邀請擔任為學校顧問。為全港首間中學中藥研究中心之發展及應用提供專業意見。
Detail